FY2025 · ended Dec 31, 2025 · Revenue $20.60M, +449.9% YoY · Filed Mar 4, 2026
Scynexis Inc (SCYX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $20.6 million and a net loss of $8.6 million. As of Sep 30, 2026 it held $47.2 million in cash and investments and $1.8 million in total debt.
Revenue (TTM)
$18.88M
+544.0% vs year-ago TTM
Net income (TTM)
$-10.10M
+60.1% vs year-ago TTM
Operating cash flow (TTM)
$-12.05M
+64.1% vs year-ago TTM
Free cash flow
$-54.56M
-10.5% vs prior year
EPS (TTM)
$-0.19
+87.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
44.66M
+14.6% vs prior year
Net cash
$45.34M
as of Sep 30, 2026
Operating margin
-126.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SCYX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Jersey City, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1178253
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $20.6M | $3.7M | $140.1M | $5.1M | $13.2M |
| Operating income | -$16.1M | -$37.1M | $72.7M | -$85.8M | -$60.8M |
| Net income | -$8.6M | -$21.3M | $67.0M | -$62.8M | -$32.9M |
| Diluted EPS | -$0.17 | -$0.44 | $1.39 | -$1.47 | — |
| Operating cash flow | -$5.3M | -$24.0M | $60.2M | -$79.9M | -$54.6M |
| Free cash flow | — | — | — | — | -$54.6M |
| Total assets | $59.0M | $90.6M | $128.4M | $87.8M | $119.8M |
| Total liabilities | $9.7M | $35.6M | $55.5M | $84.6M | $78.6M |
| Stockholders' equity | $49.4M | $55.1M | $73.0M | $3.2M | $41.3M |
| Cash and investments | $40.0M | $59.3M | $74.4M | $73.5M | $104.5M |
| Total debt | $2.2M | $2.6M | $2.9M | $3.2M | $37.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 28, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 22, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Sep 10, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results, Other events
|
Jun 26, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
May 29, 2026 | May 28, 2026 |
All 742 Scynexis Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.